Kairos Pharma, a Phase 2 biotech developing therapies for cancer, filed on Friday with the SEC for an initial public offering. The company did not disclose a proposed deal size, but we estimate the company could raise around $10 million.
Kairos Pharma is focused on advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. Bolstered by its 2021 acquisition of Enviro Therapeutics, the company's pipeline contains seven candidates, including KROS drugs (immunotherapies) and ENV antibodies. Its most advanced candidates include KROS 201, an autologous T cell therapy that is undergoing preparation for a Phase 1 trial in recurrent glioblastoma, and ENV 105, an antibody targeting CD105/Endoglin that is being tested in a randomized multicenter Phase 2 trial for prostate cancer and a Phase 1 trial in lung cancer, both of which began enrolling patients in September 2023.
The Los Angeles, CA-based company was founded in 2013 and plans to list on the Nasdaq under the symbol KAPA. Boustead Securities is the sole bookrunner on the deal. No pricing terms were disclosed.
